Korro Bio to End Novo Nordisk Research and License Collaboration
Korro Bio received notice that Novo Nordisk elected to terminate the research collaboration and license agreement for convenience, effective February 1, 2027. The agreement covered an exclusive worldwide license for a cardiometabolic target; Novo Nordisk did not nominate a second target.